CSF1R and neoplasm: The targeted drug Regorafenib (an inhibitor of multiple protein kinases, including kinases involved in tumor angiogenesis (VEGFR1, −2, −3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF, BRAFv600E), metastasis (VEGFR3, PDGFR, FGFR), and the antitumor immune response (CSF1R)), prescribed for the treatment of STS, also has an effect on TAMs, providing repolarization in the direction of M1 macrophages [107].